Elanix Signs Supply & Manufacturing Agreements with Sincopharm & Tec-Pharma for Production of Medical Cosmetics Acquired from...
October 10 2016 - 2:00AM
Business Wire
Elanix Biotechnologies AG (FSE:ELN), a developer of tissue
regeneration products, announced today the signing of supply
agreements with two Swiss companies, Sincopharm SA and Tec-Pharma
SA. The agreements will assure manufacturing sustainability at high
quality and supply reliability of two commercially available
medical cosmetic products, to alleviate gynecological and
dermatological conditions, obtained from the recent acquisition of
Repair-A SA.
Elanix now has complete control of the formulation, production
and commercialization worldwide for the two progenitor cell-based
products GynRepair, a treatment for vulvodynia and RepAir-A, a
dermatological used to rejuvenate the skin following damage. Elanix
anticipates significant sales growth for these products in the next
12 months through combination of direct and distributor sales
initially in Switzerland and Europe.
“These agreements allow Elanix to ensure our customers continue
to have access to these innovative products. There is significant
demand for effective and proven medical cosmetics, and we are now
uniquely placed to access these growing markets,” Tomas Svoboda,
CEO, Elanix Biotechnologies AG stated. “Our OTC division, headed by
Bruno Tenaille, will now begin to roll out a comprehensive
marketing and sales strategy to reach as many existing and new
customers as possible.”
Both based in Switzerland, Sincopharm SA is dedicated to
development and manufacturing of cosmetic formulations. It was
established in 1989 by two pharmacists Pierre and Christian Aubort.
Tec-Pharma SA is a cosmetic developer and manufacturer of
biological actives for a range of applications for both human and
veterinary use.
Elanix Biotechnologies (Frankfurt: ELN) develops and
commercializes tissue regeneration products for acute wound care,
dermatological and gynecological applications, and provides
services in cell technologies. The company was founded in 2013 as a
spin-out from the University Hospital of Lausanne (CHUV),
Switzerland, to commercialize a patented progenitor cell
technology. Progenitor cells are fully differentiated yet
immunologically neutral cells that are very potent inducers of
tissue growth and healing. Elanix owns GMP certified Master and
Working cell banks with vast quantities of cells of different cell
types.
The Company is headquartered in Nyon, Switzerland with offices
in Potsdam and listed on the Frankfurt stock exchange under the
symbol ELN. For more information and updates, visit
www.elanix-biotechnologies.com.
Disclaimer / Forward-looking statements:
This publication may contain certain forward-looking statements
concerning the Company and its business. Such statements involve
certain risks, uncertainties and other factors which could cause
the actual results, financial condition, performance or
achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore
not place undue reliance on these statements, particularly not in
connection with any contract or investment decision. The Company
disclaims any obligation to update these forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161009005055/en/
Press:Elanix Biotechnologies AGTomas Svoboda,
+41225520971CEOinvestor.relations@elanix.ch